TGA approval

Lecanemab (Leqembi) approved in Australia for early-stage Alzheimer’s treatment. Learn about eligibility, side effects, monitoring, and implications for patients and healthcare. Australia Approves Lecanemab (Leqembi) for Early-Stage Alzheimer’s Treatment In a significant advancement for Alzheimer’s disease management, Australia’s Therapeutic Goods Administration (TGA) has approved lecanemab, marketed as Leqembi, for the treatment of early-stage Alzheimer’s disease….